105 related articles for article (PubMed ID: 38722184)
1. Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.
Chen L; Luo R; Ma L; Xu Y; Cao J; Jiang Z; Chen S; Huang X; Zhang M; Zheng L; Zhang Y; Yin L; Yu J; Zheng X; Zheng L; Huang P; Liang G
J Med Chem; 2024 May; 67(10):8060-8076. PubMed ID: 38722184
[TBL] [Abstract][Full Text] [Related]
2. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.
Zhang J; Fu L; Shen B; Liu Y; Wang W; Cai X; Kong L; Yan Y; Meng R; Zhang Z; Chen YP; Liu Q; Wan ZK; Zhou T; Wang X; Gavine P; Del Rosario A; Ahn K; Philippar U; Attar R; Yang J; Xu Y; Edwards JP; Dai X
Cell Chem Biol; 2020 Dec; 27(12):1500-1509.e13. PubMed ID: 32888499
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of IRAK1 and IRAK4 prevents endothelial inflammation and atherosclerosis in ApoE
Wu X; Xu M; Liu Z; Zhang Z; Liu Y; Luo S; Zheng X; Little PJ; Xu S; Weng J
Pharmacol Res; 2022 Jan; 175():106043. PubMed ID: 34954030
[TBL] [Abstract][Full Text] [Related]
4. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.
Zhai W; Lu Y; Zhu Y; Zhou M; Ye C; Shi ZZ; Qian W; Hu T; Chen L
Bioorg Med Chem Lett; 2021 Jan; 31():127686. PubMed ID: 33242574
[TBL] [Abstract][Full Text] [Related]
6. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
[TBL] [Abstract][Full Text] [Related]
7. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.
Cushing L; Winkler A; Jelinsky SA; Lee K; Korver W; Hawtin R; Rao VR; Fleming M; Lin LL
J Biol Chem; 2017 Nov; 292(45):18689-18698. PubMed ID: 28924041
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
[TBL] [Abstract][Full Text] [Related]
9. A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease.
Huang Y; Ning Y; Chen Z; Song P; Tang H; Shi W; Wan Z; Huang G; Liu Q; Chen Y; Zhou Y; Li Y; Zhan Z; Ding J; Duan W; Xie H
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675622
[TBL] [Abstract][Full Text] [Related]
10. Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation.
Pfaffenbach M; Bolduc PN; Xin Z; Gao F; Evans R; Fang T; Chodaparambil JV; Henry KL; Li P; Mathieu S; Metrick C; Vera Rebollar JA; Gu RF; Mccarl CA; Silbereis J; Peterson EA
J Med Chem; 2024 May; 67(10):8383-8395. PubMed ID: 38695469
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
Chaudhary D; Robinson S; Romero DL
J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice.
Wang H; Zhou H; Zhang Q; Poulsen KL; Taylor V; McMullen MR; Czarnecki D; Dasarathy D; Yu M; Liao Y; Allende DS; Chen X; Hong L; Zhao J; Yang J; Nagy LE; Li X
J Hepatol; 2020 Dec; 73(6):1470-1481. PubMed ID: 32682051
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
Lee KL; Ambler CM; Anderson DR; Boscoe BP; Bree AG; Brodfuehrer JI; Chang JS; Choi C; Chung S; Curran KJ; Day JE; Dehnhardt CM; Dower K; Drozda SE; Frisbie RK; Gavrin LK; Goldberg JA; Han S; Hegen M; Hepworth D; Hope HR; Kamtekar S; Kilty IC; Lee A; Lin LL; Lovering FE; Lowe MD; Mathias JP; Morgan HM; Murphy EA; Papaioannou N; Patny A; Pierce BS; Rao VR; Saiah E; Samardjiev IJ; Samas BM; Shen MWH; Shin JH; Soutter HH; Strohbach JW; Symanowicz PT; Thomason JR; Trzupek JD; Vargas R; Vincent F; Yan J; Zapf CW; Wright SW
J Med Chem; 2017 Jul; 60(13):5521-5542. PubMed ID: 28498658
[TBL] [Abstract][Full Text] [Related]
14. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
[TBL] [Abstract][Full Text] [Related]
15. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
[TBL] [Abstract][Full Text] [Related]
16. A small molecule potent IRAK4 inhibitor abrogates lipopolysaccharide-induced macrophage inflammation in-vitro and in-vivo.
Choudhary SA; Patra D; Sinha A; Mazumder S; Pant R; Chouhan R; Jha AN; Prusty BM; Manna D; Das SK; Tikoo K; Pal D; Dasgupta S
Eur J Pharmacol; 2023 Apr; 944():175593. PubMed ID: 36804543
[TBL] [Abstract][Full Text] [Related]
17. Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4).
Genung NE; Guckian KM
Prog Med Chem; 2017; 56():117-163. PubMed ID: 28314411
[TBL] [Abstract][Full Text] [Related]
18. A novel benzenediamine derivate rescued mice from experimental sepsis by attenuating proinflammatory mediators via IRAK4.
Dou H; Song Y; Liu X; Yang L; Jiang N; Chen D; Li E; Tan R; Hou Y
Am J Respir Cell Mol Biol; 2014 Aug; 51(2):191-200. PubMed ID: 24588661
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors.
Wang J; Rong Q; Ye L; Fang B; Zhao Y; Sun Y; Zhou H; Wang D; He J; Cui Z; Zhang Q; Kang D; Hu L
J Med Chem; 2024 May; 67(9):7197-7223. PubMed ID: 38655686
[TBL] [Abstract][Full Text] [Related]
20. IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer.
Li Q; Chen Y; Zhang D; Grossman J; Li L; Khurana N; Jiang H; Grierson PM; Herndon J; DeNardo DG; Challen GA; Liu J; Ruzinova MB; Fields RC; Lim KH
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31527315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]